Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2018-04-30 AGM Information
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
PR in English
AGM Information Classification · 1% confidence The document explicitly announces that Innate Pharma will hold its 'ANNUAL GENERAL MEETING OF SHAREHOLDERS' on May 29, 2018, and details the procedures for participation and voting. While it mentions the release of the Reference Document, the primary subject and focus of this communication is the upcoming AGM and the associated documentation/rules for shareholders. This aligns directly with the definition of 'AGM Information' (AGM-R), which covers presentations and materials shared during the AGM, or preparatory information leading up to it. It is not the full 10-K, an earnings release, or a proxy statement (PSI), but rather a notice and information package centered around the AGM event itself.
2018-04-30 English
Document de référence 2017
Annual Report Classification · 1% confidence The document is titled 'Document de référence' (Reference Document) for Innate Pharma S.A. for the year 2017. In the French regulatory context, the 'Document de référence' is the equivalent of an Annual Report (10-K equivalent), containing comprehensive financial statements, management discussion and analysis, governance information, and risk factors. It is a full-length report, not an announcement or a summary, and it includes detailed financial tables and audit references. FY 2017
2018-04-27 French
CP en français
Earnings Release Classification · 1% confidence The document is a press release dated April 17, 2018, announcing 'DONNÉES PRÉLIMINAIRES D'ACTIVITÉ PROMETTEUSES' (Promising Preliminary Activity Data) regarding a clinical trial combination (Monalizumab and Cetuximab) presented at the AACR annual congress. It details clinical results (partial responses, safety profile, patient enrollment status) and includes commentary from the Principal Investigator and the Chief Medical Officer. This content structure—announcing key preliminary results from a medical conference presentation—is characteristic of an Earnings Release (ER) or a general press release detailing operational/clinical progress. Since it focuses on the immediate release of key financial/operational results (even if clinical data), 'ER' (Earnings Release) is the most appropriate fit among the provided options for a company announcing significant, period-specific operational achievements outside of a formal quarterly/annual report structure. It is not a full transcript (CT), a formal annual report (10-K), or a dedicated investor presentation (IP), but rather the initial announcement of these findings. FY 2018
2018-04-17 French
PR in English
Earnings Release Classification · 1% confidence The document is a press release dated April 17, 2018, announcing preliminary data from an ongoing clinical trial (Phase I/II) regarding the combination of monalizumab and cetuximab in SCCHN patients. It highlights key efficacy and safety results, includes quotes from investigators and the CMO, and mentions that the data is being presented at the AACR Annual Meeting. This format—a formal announcement of clinical trial results outside of a mandated periodic financial filing (like 10-K or IR)—is characteristic of an Earnings Release (ER) if it were tied to a reporting period, or more generally, a press release detailing operational/clinical progress. Since it is a specific announcement of clinical trial results and operational updates, and not a full financial report, a transcript, or a formal regulatory filing like a 10-K, it best fits the 'Earnings Release' category (ER) as it functions as the primary communication of recent performance/progress to the market, even if the performance metric is clinical success rather than revenue. It is not a Call Transcript (CT) as it is a written release, nor is it a Report Publication Announcement (RPA) because it contains the substantive data, not just a notice that a report is available (it even links to the poster). Given the context of biotech/pharma reporting, clinical updates often substitute for or accompany traditional earnings releases in terms of market impact. FY 2018
2018-04-17 English
CP en français
Investor Presentation Classification · 1% confidence The document is a press release dated April 17, 2018, announcing the presentation of new preclinical data from Innate Pharma's immunotherapy pipeline at the AACR 2018 annual meeting. It details scientific findings related to monalizumab combinations, CD39/CD73 targeting, and Siglec-9. This type of announcement, focusing on scientific updates, clinical trial rationales, and pipeline progress, is characteristic of an Investor Presentation (IP) or a general scientific update, rather than a formal regulatory filing like a 10-K, an Earnings Release (ER), or a simple Report Publication Announcement (RPA). Since it presents detailed scientific rationale and pipeline updates intended for investors and the scientific community, Investor Presentation (IP) is the most fitting category, even though it's structured as a press release.
2018-04-17 French
PR in English
Investor Presentation Classification · 1% confidence The document is a press release dated April 17, 2018, announcing the presentation of new preclinical data from Innate Pharma's portfolio at the American Association for Cancer Research (AACR) Annual Meeting. It details scientific findings related to monalizumab combinations and new antibody programs (IPH52, IPH53, anti-Siglec-9). This content is typical of an update provided to investors and the scientific community regarding ongoing research and development progress, often released concurrently with or immediately following a scientific conference presentation. It is not a formal regulatory filing like a 10-K, a formal earnings release (ER), or a transcript (CT). Since it is a detailed presentation of scientific/pipeline progress aimed at investors, the most appropriate classification is Investor Presentation (IP). It is not a general Regulatory Filing (RNS) because it fits the specific 'IP' definition better.
2018-04-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.